

# **Rudhira/BCAS3 is essential for mouse development and cardiovascular patterning.**

Ronak Shetty<sup>1#</sup>, Divyesh Joshi<sup>1#</sup>, Mamta Jain<sup>1</sup>, Madavan Vasudevan<sup>3</sup>, Jasper Chrysolite Paul<sup>1</sup>, Ganesh Bhat<sup>1</sup>, Poulomi Banerjee<sup>1</sup>, Takaya Abe<sup>2</sup>, Hiroshi Kiyonari<sup>2</sup>, K. VijayRaghavan<sup>4</sup> and Maneesha S. Inamdar<sup>1,5\*</sup>

## **Inventory of Supplementary Information**

1. Supplementary information
  - a. Supplementary text
  - b. Supplementary Figure 1
  - c. Supplementary Figure 2
  - d. Supplementary Figure 3
  - e. Supplementary Figure 4
  - f. Supplementary Figure 5
2. Supplementary Table 1
3. Supplementary Table 2
4. Supplementary Table 3
5. Supplementary Table 4
6. Supplementary Table 5
7. Supplementary Table 6
8. Supplementary Table 7
9. Revised main text with tracked changes
10. Revised supplemental text with tracked changes

1 **Rudhira/BCAS3 is essential for mouse development and cardiovascular**  
2 **patterning.**

3

4 Ronak Shetty<sup>1#</sup>, Divyesh Joshi<sup>1#</sup>, Mamta Jain<sup>1</sup>, Madavan Vasudevan<sup>3</sup>, Jasper Chrysolite Paul<sup>1</sup>, Ganesh  
5 Bhat<sup>1</sup>, Poulomi Banerjee<sup>1</sup>, Takaya Abe<sup>2</sup>, Hiroshi Kiyonari<sup>2</sup>, K. VijayRaghavan<sup>4</sup> and Maneesha S. Inamdar<sup>1,5\*</sup>

6

7

8 **Supplementary materials and methods**

9

10 **Genotyping**

11 Genomic DNA was extracted from cultured ectoplacental cone at E7.5, yolk sacs at E8.5 and tails of E9.5  
12 or older embryos. Primers used (Table S7) to identify genotypes of *rudhira* were: RudGNWT (F and R) for  
13 wild type allele; RudGNMUTF and RudGNWTR for the floxed allele; RudLoxR2 and RudGNMUTF for  
14 excision of the floxed allele. *Cre* positive mice were identified by PCR using primers CreF and CreR.  
15 Reactions were subjected to 30 cycles of denaturation at 94°C for 1 min, annealing at 56°C for 1 min and  
16 extension at 72°C for 1 min.

17

18 **Quantitative RT-PCR (qRT-PCR)**

19 RNA from E9.5 yolk sac or endothelial cells was isolated using TRIzol reagent (Invitrogen). Reverse  
20 transcription was performed using 2 µg of DNase treated RNA and Superscript II (Invitrogen, Carlsbad, CA)  
21 according to manufacturer's instructions. Quantitative RT-PCR (qRT-PCR) was carried out using EvaGreen  
22 (BIO-RAD, CA) in Biorad-CFX96 Thermal cycler (BIO-RAD, CA). Primers used are provided in Table S7.

23

24 **Immunostaining and Immunohistochemistry**

25 Primary antibodies used were against Rudhira (1:10)<sup>1</sup>, PECAM1 (1:50, cat. no. 557355), Flk1 (1:50, cat. no.  
26 555307), Ly76 (1:50, cat. no. 553670) (BD Biosciences), Brachyury (1:50, cat. no. sc-17743) (Santa Cruz  
27 Biotechnology), Smooth Muscle Actin (1:10000, cat. no. A2547) (Sigma Chemical Co. USA). Secondary  
28 antibodies were coupled to Alexa-Fluor 488 or Alexa-Fluor 568 or Alexa-Fluor 633 (Molecular Probes).  
29 Cryosections were stained with haematoxylin and eosin using standard protocols.

30

31 **Fluorescence Microscopy and Analysis**

32 Bright field and phase contrast microscopy was done using a stereo zoom (SZX12 Olympus) or inverted  
33 (IX70, Olympus) microscope. Confocal microscopes (LSM 510 Meta and LSM 880 with airy scan, Zeiss) and  
34 a motorized inverted microscope with fluorescence attachment (IX81, Olympus) were used for  
35 fluorescence microscopy. Images were captured using a CCD camera (CoolSNAP, Roper Scientific) or an  
36 EM CCD camera (Andor, LucaR). All images in a set were adjusted equally for brightness and contrast using  
37 Adobe Photoshop CS2 where required.

38

### 39 **Microarray data analysis**

40 RNA integrity and quality were analyzed by 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA). 500  
41 ng of total RNA for each sample was used to generate biotin-labelled cRNA using IlluminaTotalPrep RNA  
42 Amplification kit according to the manufacturer's protocol (Illumina Cat. No. AMIL1791) and subjected to  
43 microarray transcriptional analysis in quadruplicate. 750 ng labelled cRNA/array was hybridized to the  
44 Illumina Mouse WG6 BeadChip (45200 transcripts, version 2) according to the manufacturer's  
45 instructions. Arrays were scanned with an Illumina Bead array Reader confocal scanner (BeadStation  
46 500GXDW) and imported into BeadStudio software for obtaining Sample Gene Profile data. Raw data  
47 obtained in .txt format were normalized using GeneSpring GX v 12.0. Intra array Quantile normalization  
48 was done for each chip / sample. Inter array normalization was done by taking median of all the samples.  
49 Volcano plot based method was used to visualize the transcripts (Fig. 3a) that are 2 fold differentially  
50 expressed (up- or down-regulated) between any two conditions (Ex: Mutant vs. Wild type) by applying  
51 Unpaired Student's t-test for p-value calculation ( $p < 0.05$ ) and Benjamini Hocheberg based FDR  
52 correction. Pairwise comparison between samples revealed a high correlation coefficient (>99%  
53 concordance). Unsupervised hierarchical clustering of differentially expressed genes was done by Pearson  
54 Uncentered algorithm with Average linkage rule to identify up- and down- regulated gene  
55 clusters. Unsupervised hierarchical clustering of samples showed replicates grouping in the same branch  
56 with very minimal distance between them indicating reproducible measurement (Fig. 3c,d). Replicate  
57 samples from the same genotype showed tight clustering. Comparison of up and down regulated genes  
58 in both Embryo and Yolk Sac was done and represented using Venn Diagram for understanding the basal  
59 differential expression profiles between two tissues (Fig. 3b).

60

### 61 **Gene ontology and pathway analysis**

62 Biological analysis of differentially expressed genes was done for Gene Ontology and Pathways using  
63 DAVID tool (<http://david.abcc.ncifcrf.gov/>). Statistically significant ontologies and pathways were filtered

64 based on  $p < 0.05$  (Obtained using Fischer Exact Test) with Benjamini Hochberg FDR correction. Key Gene  
65 Ontology categories and Pathways that were enriched were represented as histogram (Fig. 3e).

66

### 67 **Biological Analysis Network (BAN)**

68 Regulatory network (nodes and edges) underlying the differential expression upon loss of *rudhira/BCAS3*  
69 gene expression was modeled by considering the key deregulated pathways and Gene Ontologies along  
70 with the differentially expressed genes harbored as an input to Bridgelsland© software (Bionivid  
71 Technology Pvt Ltd, Bangalore, India). Output of the software results in identification of key nodes and  
72 edges enriched in a gene: process manner. Further, the output was imported to Cytoscape v 8.3<sup>2</sup> to  
73 visualize the biological network to understand key regulatory genes and processes. Force Directed Spring  
74 Embedded algorithm was applied to model the network and visualized. Nodes were sized based on their  
75 p-Value and colored based on their fold change in mutant in comparison to wild type sample.  
76 Experimental data from pre-published studies and from this experiment was used to create the BCAS3  
77 regulatory network using Cytoscape V 8.3 by applying Hierarchical Layout algorithm (Fig. 3f).

78

### 79 **Data availability**

80 All relevant data are within the paper and its Supplementary Information files. All reported microarray  
81 data are MIAME compliant and raw data have been deposited in NCBI's Gene Expression Omnibus and  
82 are accessible through GEO Series accession number

83 (<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE69204>) a MIAME compliant database.

84

### 85 **Generation of knockdown EC lines**

86 Saphenous vein endothelial cell line (SVECs) was obtained from Kaustabh Rau, National Centre for  
87 Biological Sciences, Bangalore) and maintained in culture medium (DMEM, 10% fetal bovine serum (FBS),  
88 1X Glutamax). *Rudhira/BCAS3*shRNA vectors (715, 716), and scrambled (non- silencing) control vector  
89 (TR30015) (Origene, USA) were microporated into SVEC according to the manufacturer's instructions  
90 (Neon; Life Technologies). The transfected cells were selected in puromycin containing media (1  $\mu\text{g}/\text{ml}$ )  
91 for 7 days and >99% RFP positive population was obtained by fluorescence associated cell sorting (FACS)  
92 using a BD Aria II (BD Pharmingen). *Rudhira/BCAS3* knockdown was validated by qRT PCR and Western  
93 blot analysis.

94

95 **References**

96 1 Jain, M., Bhat, G. P., Vijayraghavan, K. & Inamdar, M. S. Rudhira/BCAS3 is a cytoskeletal protein  
97 that controls Cdc42 activation and directional cell migration during angiogenesis. *Exp Cell Res*  
98 **318**, 753-767, doi:S0014-4827(12)00037-7 [pii]

99 10.1016/j.yexcr.2012.01.016 (2012).

100 2 Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular  
101 interaction networks. *Genome research* **13**, 2498-2504 (2003).

102

103

104

105 **Supplementary figure legends**

106

107 File: Fig\_S1

108 **Supplementary Fig. S1 (related to Figs. 1 to 4, 7). Validation and analysis of *rudhira* knockout mice.** (a)

109 Southern blotting analyses to confirm heterozygous floxed *rudhira* mice. Arrows represent the shifted

110 band due to insertion. Positive clones are marked with asterisks. (b) Embryo sections stained for Rudhira

111 (green) showing expression in control and *rudh*<sup>-/-</sup> as indicated. Nuclei are marked by DAPI (Blue). (c)

112 Validation of *rudhira* knockout by western blotting. (d, e, e') Phase contrast images of control and *rudh*<sup>-/-</sup>

113 embryos at E7.5 and E8.5. Whole mount staining for Brachyury (Green) at E7.5 and Flk1 (Red) in aortic

114 primordia at E8.5 (boxed regions) is also shown. (e') Phase contrast and immunostaining of ~8 somite

115 *rudh*<sup>-/-</sup> embryo, a stage comparable to wild type. Arrows point to discontinuous Flk1 staining in aorta. (f)

116 Representative image showing measurements made on the embryo. Graphs show the quantitation of

117 curved length (black line), head to heart distance (blue line), length (red line) and width (green line) of

118 control and *rudh*<sup>-/-</sup> embryos. Scale bar: (b) 50 μm; (d) 200 μm; (e) 300 μm.

119

120 File: Fig\_S2

121 **Supplementary Fig. S2 (related to Fig. 1). Vascular remodeling defects in *rudhira* null embryos.** Whole

122 mount PECAM staining in control and *rudh*<sup>-/-</sup> yolk sacs as indicated. Boxed regions are magnified in the

123 adjacent panels. Red dots: primary blood vessel; green dots: secondary blood vessel; yellow dots: tertiary

124 blood vessel. Scale bar: 200 μm.

125

126 File: Fig\_S3

127 **Fig. S3. (related to Figs. 3, 4). Rudhira depletion deregulates multiple networks essential for**

128 **angiogenesis.** (a-f) Unsupervised hierarchical clustering computed with Pearson Uncentered algorithm

129 with average linkage rule and regulatory networks of differentially expressed genes and biological

130 processes significantly deregulated in *rudh*<sup>-/-</sup> yolk sac compared to control. Network maker program

131 (Bionivid Technology Pvt Ltd) was used to identify the nodes and edges that form the regulatory circuit

132 and Cytoscape V 8.0 was used to visualize the network. Edge weighted spring embedded layout was used

133 to visualize the network.

134

135 File: Fig\_S4

136 **Supplementary Fig. S4 (related to Figs. 5, 6). Validation and analysis of *rudhira* CKO mice.** (a) Embryo  
137 sections stained for Rudhira (green) and Flk1 (red) showing expression in control and *rudh*<sup>CKO</sup> as indicated.  
138 Nuclei are marked by DAPI (Blue). (b, c) Validation of CKO by RT (b) and immunoblot (c). Scale bar: (a) 50  
139  $\mu\text{m}$ .

140

141 **Supplementary Fig. S5 (related to Fig. 4). Full-length pictures for western blots.** Full-length pictures for  
142 western blots presented in Fig. 4, S1 and S4. Membranes were cut to enable probing with multiple  
143 antibodies.

144 **Supplementary table legends**

145

146 File: Table\_S1

147 **Supplementary Table 1. Analysis of embryo genotypes and lethality mapping.**

148

149 File: Table\_S2

150 **Supplementary Table 2. List of differentially regulated genes in *rudh*<sup>-/-</sup>embryo and yolk sac.**

151

152 File: Table\_S3

153 **Supplementary Table 3. List of common genes (up-regulated and down-regulated) in *rudh*<sup>-/-</sup>embryo  
154 and yolk sac.**

155

156 File: Table\_S4

157 **Supplementary Table 4. List of dysregulated biological categories in *rudh*<sup>-/-</sup>embryo and yolk sac.**

158

159 File: Table\_S5

160 **Supplementary Table 5. List of genes for individual network (adhesion, angiogenesis, cytoskeleton,  
161 ECM organization, peptidase activity and TGFβ signaling).**

162

163 File: Table\_S6

164 **Supplementary Table 6. List of BCAS3 pathway genes in the Cytoscape model (related to Fig 3f).**


165

166 File: Table\_S7

167 **Supplementary Table 7. List of primers.**


168






**Figure S1**



Control



Inset




*rudh*  $-/-$




**Figure S2**






**Figure S4**


related to Figure 4



related to Figure S1



related to Figure S4



**Figure S5**

**A**

dpc	No. of embryos	+/+	+/-	-/-
8.5	100	21 (21%)	63 (63%)	16 (16%)
9.5	235	58 (24.68%)	151 (64.25%)	26 (11.06%)
10.5	17	4 (23.53%)	12 (71%)	1 (5.88%)
11.5	13	6 (46.15%)	7 (53.85%)	0 (0%)
Postnatal	96	24 (25%)	72 (75%)	0 (0%)

**B**

dpc	No. of embryos	+/+	+CKO	CKO
9.5	33	9 (27.27%)	17 (51.52%)	7 (21.21%)
10.5	107	17 (15.8%)	68 (63.55%)	22 (20.56%)
11.5	49	12 (24.48%)	28 (57.14%)	9 (18.36%)
12.5	11	3 (27.27%)	6 (54.55%)	2 (18.18%)
13.5	24	9 (37.50%)	14 (58.33%)	1 (4.16%)
Postnatal	17	7 (41.17%)	10 (58.83%)	0 (0%)

**Table S1: Analysis of embryo genotypes and lethality mapping.**

**Table: List of genotyping primers**

No	Primer name	Primer sequence (5'- 3')
1	RudGNWTF	TCATGGTGTAGCTAGTGTGG
2	RudGNWTR	CCTGCATTCCGTCACTGTAG
3	RudGNMUTF	AATGGAAGGATTGGAGCTACG
4	RudLoxR2	AATCCCACAACCTGCTGCTAC
5	Cre F	ATCCGAAAAGAAAACGTTGA
6	Cre R	ATCCAGGTTACGGATATAGT

**Table: List of RT PCR primers**

No	Gene	Forward primer (5'- 3')	Reverse primer (5'-3')	Amplicon size (bp)
1	Gapdh	GGTGAGGCCGGTGCTGAG	CCTGCCAAGTATGATGACATC A	514
2	Rudhira	TGCAGCCATGGACGACACAT CACAGAATCTAG	GAAGTGCTCGAGAATGCCATC ACTGTCCGAG	800

**Table: List of qPCR primers**

No	Gene	Forward primer (5'- 3')	Reverse primer (5'-3')
1	Aebp1	TCCGTATACCTGGGCTGTGA	TGCTCATCTGTCACCCACACC
2	Arhgef7	CCTGGACAAGTACCCACAC	AGCTCCTTCCTCTTGCGAAC
3	Bai1	CCTAATCACTCACTCACCCCTC	TGCTTCTCTGGCTTGCTGTC
4	Bai2	CACACTTTTCGACCGCTACC	GCCTCCTGTGCTGGGAC
5	Bambi	CTACTGTGATGCTGCCCCAC	TGCTTGCAAGAGAGTCCAGG

6	Bmp2	TGGAAAAGGACATCCGCTCC	TCTTGCAGCTGGACTTGAGG
7	Bmp4	GCCATTGTGCAGACCCTAG	ACCCCTCTACCACCATCTC
8	Cldn11	GTGGCTGTTTGCTCTTTCCT	TCAGCAATGTTCCCAAGACA
9	Cntn2	TGGTCTCCTCTCCAGGATGG	GGAATAGCAGGCCAACAGGT
10	Coro1a	AAATTCCGCCACGTGTTTGG	AGTCTTGCCTAGGGGTAGCA
11	Dsg4	GCCACCTTACGGAGTGTTCA	GAGAGCTCGGCAATGGATCA
12	Esm1	CAGTATGCAGCAGCCAAATC	GATGCTGAGTCACGCTCTGT
13	Fgf2	CCAACCGGTACCTTGCTATG	GTCCCGTTTTGGATCCGAG
14	F2r	TGGAGGGTAGGGCAGTCTAC	TACACGGAGGGCATGAAGAG
15	Fos	GGGCTCTCCTGTCAACACAC	CTGGTGGAGATGGCTGTCAC
16	Gapdh	GGTGAGGCCGGTGCTGAG	TGATGTCATCATACTTGGCAGG
17	Hnf4a	GCCTTCTGCGAACTCCTTCT	GTCATCTCCGCTAGCTCTG
18	Hes5	AACTCCAAGCTGGAGAAGGC	GTCAGGAACTGTACCGCCTC
19	Igfbp7	AAGAGGCGGAAGGGTAAAGC	CTGGGGTAGGTGATGCCG
20	Ins2	GACCCACAAGTGGCACAAC	TCTACAATGCCACGCTTCTG
21	Igf1	CTCTGCTTGCTCACCTTCAC	CACACGAACTGAAGAGCATCC
22	Ins3	CATGCGCGCGCCGCTGCTAC	TCAGTGGGGACACAGACCC
23	Itga4	TATGGCTGCGGAAGCGAG	CACCACCGAGTAGCCAAACA
24	Itgav	GGTGTGGATCGAGCTGTCTT	CAAGGCCAGCATTTACAGTG
25	Itga9	CAGGCCGGAATAGCAGGC	GTGGCCAGCCGTCACTGC
26	Kdr	GCGGAGACGCTCTTCATAAT	CACTTGCTGGCATCATAAGG
27	Knk1	CCTACATTGCCAGGGAGCAA	GCTTTTCATGCAACCAGCCA
28	Mmp-2	CAGGGAATGAGTACTGGGTC	ACTCCAGTTAAAGGCAGCATC
29	Mmp-9	GTCCAGACCAAGGGTACAGC	ATACAGCGGGTACATGAGCG



30	Mmp-10	ATGGACACTTGCACCCTCAG	GTGGAAGTTAGCTGGGCTTG
31	Mmp-21	ACACAGGCATCAGCCTTCTC	AATGACCCCTTGCACGAACC
32	Mmp-25	CTGGCTGTCTGGGCTACTG	GGTAGGCCCGAGCAAAGTG
33	Myh6	TCTGCCTACCTTATGGGGCT	ACTTGCTGTACACTCTGCCC
34	Plat	AGATGAGCCAACGCAGAC	AACTTCGGACAGGCACTG
35	Plg	CGTGGGTTGGATGTTTCAGGA	GTCCGGTCAGCAACCATGTA
36	Ppbp	CGTTGTTCCCTCCTGGCTCT	GGACGATGTAGGTCTGAGTC
37	Ptpm	TGTCGGAGCAACCTATCTGTG	CTGGCTGCCGATCATTCCAG
38	rudhira	TCCTACATGGAGAGCGTCG	GGAGGCTCATTTCAGTGC
39	Serpinb2	TTCCGTGTGAACTCGCATGA	TGCGTCCTCAATCTCATCGG
40	Serpinf2	ACTCTGTACCATCCCTCGCT	ATGTTGCACGCTAGACACCA
41	Smad6	GGGTGAATTCTCAGACGCC	GGTCGTACACCGCATAGAGG
42	Smad7	CCCATCACCTTAGCCGACTC	GCACAGCATCTGGACAGTC
43	Smurf1	AGGAGGGAATTGCAGGTTTCG	AGTGAACCTCGCACATCAGG
44	Smurf2	TGGGAAGAAAGGAGAACCGC	CAGCTAAGAGGTCTGCCAGG
45	Sox9	GTGCAAGCTGGCAAAGTTGA	TGCTCAGTTCACCGATGTCC
46	Spi1-3	GAAGCTGCAGCAGTTACAGTC	TGTGGGATCTACCACTTTTCC
47	Tgfb2	TTTAAGAGGGATCTTGGATGG	AGAATGGTCAGTGGTTCCAG
48	Tgfb3	CGCACAGAGCAGAGAATTG	TGACATGGACAGTGGATGC

49	Tgfbr2	CCCAAGTCGGATGTGGAAATG	CGCTGGCCATGACATCACTG
50	Vash1	CCATACCAAGTGTGCCTAC	AGAATTGTGTCCCTGTGTG
51	Vim	GAGAACTTTGCCGTTGAAGC	GCTTCCTGTAGGTGGCAATC
52	Vtn	CCCCTGAGGCCCTTTTTCA	CAAAGCTCGTCACACTGAC